PRVB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PRVB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Provention Bio's Operating Income for the three months ended in Dec. 2022 was $-40.17 Mil. Provention Bio's Interest Expense for the three months ended in Dec. 2022 was $-0.78 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Provention Bio's Interest Coverage or its related term are showing as below:
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Provention Bio's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Provention Bio Annual Data | ||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||
Interest Coverage | Get a 7-Day Free Trial | No Debt | No Debt | N/A | N/A | - |
Provention Bio Quarterly Data | ||||||||||||||||||||
Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | |
Interest Coverage | Get a 7-Day Free Trial | N/A | N/A | N/A | - | - |
For the Biotechnology subindustry, Provention Bio's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Provention Bio's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Provention Bio's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
If Interest Expense is negative and Operating Income is positive, then
Interest Coverage | = | -1 | * | Operating Income | / | Interest Expense |
Else if Interest Expense is negative and Operating Income is negative, then
The company did not have earnings to cover the interest expense. |
Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then
The company had no debt (1). |
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Provention Bio's Interest Coverage for the fiscal year that ended in Dec. 2022 is calculated as
Here, for the fiscal year that ended in Dec. 2022, Provention Bio's Interest Expense was $-1.04 Mil. Its Operating Income was $-128.16 Mil. And its Long-Term Debt & Capital Lease Obligation was $23.91 Mil.
Provention Bio did not have earnings to cover the interest expense. |
Provention Bio's Interest Coverage for the quarter that ended in Dec. 2022 is calculated as
Here, for the three months ended in Dec. 2022, Provention Bio's Interest Expense was $-0.78 Mil. Its Operating Income was $-40.17 Mil. And its Long-Term Debt & Capital Lease Obligation was $23.91 Mil.
Provention Bio did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's Financial Strength is.
Provention Bio (NAS:PRVB) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Thank you for viewing the detailed overview of Provention Bio's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.
Sessa Capital (master), L.p. | 10 percent owner | 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019 |
Ashleigh Palmer | director, 10 percent owner, officer: President and CEO | PROVENTION BIO, INC., 110 OLD DRIFTWAY LANE, LEBANON NJ 08833 |
Francisco Leon | director, 10 percent owner, officer: Chief Scientific Officer | C/O PROVENTION BIO, INC., 110 OLD DRIFTWAY LANE, LEBANON NJ 08833 |
Jason Hoitt | officer: Chief Commercial Officer | C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707 |
Justin Vogel | officer: Chief Accounting Officer | C/O PROVENTION BIO, INC., 55 BROAD STREET, RED BANK NJ 07701 |
Rita Jain | director | C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142 |
Sarah O'brien | officer: Chief People Officer | C/O PROVENTION BIO, INC., 55 BROAD STREET, RED BANK NJ 07701 |
Sessa Capital Im, L.p. | 10 percent owner | 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019 |
John Petry | 10 percent owner | 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019 |
Sessa Capital Gp, Llc | 10 percent owner | 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019 |
Sessa Capital Im Gp, Llc | 10 percent owner | 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019 |
Miyoko Christina Yi | officer: Chief Operations Officer | C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK NJ 07701 |
Benedict Osorio | officer: Chief Quality Officer | ONE WORLD TRADE CENTER, 47TH FLOOR, SUITE J, NEW YORK NY 10007 |
Eleanor Ramos | officer: Chief Medical Officer & COO | ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE E, SEATTLE WA 98102 |
Thierry Chauche | officer: Chief Financial Officer | C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK NJ 07701 |
From GuruFocus
By PRNewswire PRNewswire • 02-08-2023
By PRNewswire PRNewswire • 11-17-2022
By PRNewswire PRNewswire • 01-06-2023
By PRNewswire PRNewswire • 07-13-2022
By PRNewswire PRNewswire • 11-03-2022
By PRNewswire PRNewswire • 08-02-2022
By PRNewswire PRNewswire • 07-11-2022
By PRNewswire PRNewswire • 02-03-2023
By PRNewswire PRNewswire • 07-28-2022
By PRNewswire PRNewswire • 08-31-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.